Seite auswählen

In June, AstraZeneca made a start and came to an arrangement with the National Association of Statutory Health Insurance Funds (Spitzenverband der GKV) regarding the reimbursement for blood diluting drug Ticagrelor (Brilique). Since then the pharmaceutical industry and the National Association of Statutory Health Insurance Funds agreed upon reimbursement prices for new drugs according to the specifications of the law re-organizing the pharmaceutical market (Arzneimittelmarkt-Neuordnungsgesetzes [AMNOG]) eleven times.

The National Association of Statutory Health Insurance Funds now stated that a fair compensation between the interests of the pharmaceutical companies and the interests of he statuory health insurance companies is possible. Eventually, only one case had to be settled by arbitration.

However, the pharmaceutical industry has a different view. „Here, one negotiating partner is more equal than the other. The first negotiations that were concluded did not change that,“ Norbert Gerbsch, Deputy Chairman of the Association of the Pharmaceuticals Industry, said. According to Gerbsch negotiated procedures have not been balanced yet. The National Association of Statutory Health Insurance Funds has an extremely strong position when it comes to negotiations and evaluations. In the Federal Joint Committee it outweighs other members with five of thirteen votes and co-determines comparative therapy and benefit resolutions. „And these therapies and resolutions are the basis for negotiating with the association“, Gerbsch said.

[ilink url=“http://www.gkv-spitzenverband.de/presse/pressemitteilungen_und_statements/pressemitteilung_15808.jsp“] Link to source (GKV-Spitzenverband)[/ilink]